Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
IntroductionImmune checkpoint inhibitors have made a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust predictive biomarkers for patient stratification are lacking. Here, we characterize early on-treatment proteomic changes in...
Main Authors: | Jair Bar, Raya Leibowitz, Niels Reinmuth, Astrid Ammendola, Eyal Jacob, Mor Moskovitz, Adva Levy-Barda, Michal Lotem, Rivka Katsenelson, Abed Agbarya, Mahmoud Abu-Amna, Maya Gottfried, Tatiana Harkovsky, Ido Wolf, Ella Tepper, Gil Loewenthal, Ben Yellin, Yehuda Brody, Nili Dahan, Maya Yanko, Coren Lahav, Michal Harel, Shani Raveh Shoval, Yehonatan Elon, Itamar Sela, Adam P. Dicker, Yuval Shaked |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1364473/full |
Similar Items
-
1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer
by: Jarushka Naidoo, et al.
Published: (2023-11-01) -
Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting
by: Moran Gadot, et al.
Published: (2022-09-01) -
Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases
by: Amke C. Beenen, et al.
Published: (2022-08-01) -
Enabling Factors in Successful Product Development
by: Tang, Victor, et al.
Published: (2014) -
Enabling Factors in Successful Product Development
by: Tang, Victor, et al.
Published: (2014)